Poteligeo Injection
NDC Package 42747-761-01
Package Information
Poteligeo (mogamulizumab-kpkc) injection is a medication used to treat certain cancers (such as mycosis fungoides, Sezary syndrome). This formulation utilizes a injection delivery system. Marketed by Kyowa Kirin, Inc., this product is identified by NDC 42747-761 and is authorized under FDA application BLA761051.
Identification & Billing
- RxCUI: 2054081 - mogamulizumab-kpkc 20 MG in 5 ML Injection
- RxCUI: 2054081 - 5 ML mogamulizumab-kpkc 4 MG/ML Injection
- RxCUI: 2054081 - mogamulizumab-kpkc 20 MG per 5 ML Injection
- RxCUI: 2054086 - POTELIGEO 20 MG in 5 ML Injection
- RxCUI: 2054086 - 5 ML mogamulizumab-kpkc 4 MG/ML Injection [Poteligeo]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 42747 - Kyowa Kirin, Inc.
- 42747-761 - Poteligeo
- 42747-761-01 - 1 VIAL, GLASS in 1 CARTON / 5 mL in 1 VIAL, GLASS
- 42747-761 - Poteligeo
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 42747-761-01 identifies a specific commercial package of 1 vial, glass in 1 carton / 5 ml in 1 vial, glass of Poteligeo, a human prescription drug labeled by Kyowa Kirin, Inc.. This injection is formulated for intravenous use and contains mogamulizumab as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Kyowa Kirin, Inc. on August 08, 2018. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This medication is used to treat certain cancers (such as mycosis fungoides, Sezary syndrome). Mogamulizumab-kpkc belongs to a class of drugs known as monoclonal antibodies. It works by changing the action of your own immune system, directing it to attack cancer cells. This effect helps slow or stop the growth of cancer cells.
How is this Kyowa Kirin, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 42747076101. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
